Founder of Synthego

Synthego was founded by brothers Paul Dabrowski and Michael Dabrowski , who worked at SpaceX , founded by Elon Musk , before officially entering the field of biological sciences .

When entering the biological field, the two founders initially targeted the field of nucleic acid synthesis, but after research, they found that large companies like Gen9 and Twist Bioscience were focusing on DNA (deoxyribonucleic acid), so they decided to specialize in RNA (ribonucleic acid) and chose to synthesize CRISPR RNA for genome editing .

Synthego Company Profile

Headquartered in Silicon Valley, Synthego's customers include leading institutions in 32 countries around the world, 8 of the world's top 10 biotech companies , and 24 of the world's top 25 biology universities .  

Synthego Core Advantages

Regarding the core advantages of Synthego's products, CRISPRevolution products can make gene editing more efficient, lower cost, and more accurate, helping scientists reduce unnecessary experimental time. Compared with traditional gene editing methods that rely on plasmids or in vitro transcription, CRISPRevolution can synthesize RNA in a high-precision automated laboratory , thereby reducing manual operation costs and achieving large-scale production of products. Compared with other synthetic RNA providers, CRISPRevolution products cost 80% less than them . In addition, the product can optimize guide RNA to make its efficiency in editing and knocking out genes in cells as high as 90% , while shortening traditional experimental preparation time from weeks to days. In addition, its synthesized RNA is of high purity and 100% free of DNA , which is a key factor in determining the success of CRISPR technology in treatment and plant genomics experiments.

Synthego Vision

Synthego 's vision is to bring precision and automation to genome engineering, enabling rapid, cost-effective research that delivers consistent results to every scientist.

Synthego builds advanced bioinformatics and automation hardware platforms to create the next generation of molecular biology tools, starting with whole-stack genome engineering.

Synthego Financing

In August 2012 , it obtained US$ 250,000 in debt financing.

In July 2013 , Synthego received approximately US$ 8 million in Series A financing from Menlo Ventures , Founders Fund , and China Economic Cooperation Group.

In 2017 , Synthego announced that it had received US$ 41 million in Series B financing. The transaction was led by 8VC , and many institutions including AME Cloud Ventures , Elements Capital , OS Fund , Alexandria Equities , ZhenFund, Jennifer Doudna , famous researcher Jamie H Doudna Cate , Founders Fund , Menlo Ventures , WI Harper Group and SciFi VC participated in this round of financing.

In October 2018 , Synthego raised $ 110 million in cash funding from new investors in Founders Fund and the company’s previous backers — 8VC and Menlo Ventures — and plans to use the money to reduce costs.

Synthego Development History

In August 2016 , ZhenFund invested in this American biotechnology company.

References